Alpha Tau Medical’s Alpha DaRT Phase 3 trials demonstrate 100% tumor response in treating solid tumors by delivering localized alpha radiation directly into lesions. Notably, the treatment elicits systemic immune activation causing regression of untreated tumors in patients and protective effects in animal models. The therapy combined with pembrolizumab shows substantially improved complete and overall response rates versus immunotherapy alone. These advances position Alpha DaRT as a promising breakthrough localized cancer treatment with broad immunotherapeutic potential.